Over 50 deadly incurable ageing-related degenerative diseases, including Alzheimer's, Parkinson's, type II diabetes and many rare diseases are now believed to be caused by the formation of toxic amyloid pores in cell membranes. Amporin Pharmaceuticals will develop the first effective disease-modifying treatments for these diseases, based on its novel proprietary series of small molecule amyloid pore inhibitors ('Amporins') and amyloid pore-targeting chimeras ('Amportacs').

ArcoScreen, spin-off of EPFL, founded in July 2021 develops a new drug screening platform targeting G Protein Coupled Receptors (GPCRs).
ArcoScreen's patented assay embedded in a microfluidic chip, called SynScreen, provides the only mean today of rapidly and accurately identifying drugs targeting GPCRs directly on primary patient cells. The implication is more accurate, cheaper, and faster drug discoveries, for the mutual benefit of patients and ArcoScreen.

Particles in parenteral drugs are critical for patient safety. Thus, sub-visible particle testing is mandatory for any parenteral preparation and is being used in drug product development and quality control. However, the technology fulfilling compendial requirements comprises many manual steps and destroys the sample during testing. Bionter offers a fully automated and non-destructive solution that is especially interesting for high priced drug products in the biotech and cells & genes sector.

Every year over 270 million exams are performed globally for early detection of breast cancer. Failing diagnoses because of human error harms patients and exposes doctors to high liability risks.
b-rayZ offers a revolutionary AI technology to healthcare professionals for faster and better breast cancer diagnostics. For every woman, everywhere.

DeepPsy's goal is to improve psychiatric treatment by using technology. In psychiatry, treatment decisions are mostly based on information obtained at the symptomatic level. To find an effective treatment, patients go through a prolonged trial-and-error process. DeepPsy helps psychiatrists identify the treatment with the highest likelihood of a positive response by analyzing brain waves (EEG) and heart activity (ECG) with scientifically validated algorithms.

Cell & gene therapies (CGT), such as CAR T-cells, are life-saving personalized medicines, but their production remains extremely challenging and expensive, limiting patient access. Limula SA provides a platform enabling cell therapy manufacturing at scale. Combined with Limula's expertise, this unique tool supports biotech companies with CGT assets, or CDMO with CGT customers, at all stages of the product life cycle, from pre-clinical R&D to patient batch production for clinical use.

Melanoma is the most aggressive skin cancer with a global market size of 3.45 billion USD in 2021. There is an unmet need for more therapeutical options, once standard therapies have failed. Lumaros currently has two compounds that show efficacy against melanoma, low toxicity and good bioavailability. These compounds are excellent candidate leads for further development into clinical therapeutic drugs.

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer mortality worldwide. The aim at Recolony is to bring a medication for CRC patients purely based on commensal bacteria: in vivo data show very high anti-tumor efficacy of this bacteria by specific activation of CD8+ T-cells. Recolony's therapy will minimize severe side-effects and reduce visits to the hospital, and it could even be applied to prevent tumor recurrence or avoid tumor development in risk patients.

The number of cancer patients is on the rise and standard therapies often fail. The reason for this is that every patient is different and due to tumor biology, therapy resistances develop over the course of the disease. As a solution, TheraMe! have developed an innovative tool that allows the efficacy of drugs and drug combinations to be tested directly on patients' tumor material within 24 hours in order to determine the best personalized therapy for the patient.

The prognosis of patients with advanced cancers remains poor and calls for improved treatments. TheraPPI wants to offer a better prognosis to those patients by developing drugs modifying protein interactions.
TheraPPI's drug against advanced cancers already has solid efficacy data in animals and plans to enter into clinical development in less than 2 years. The vision for TheraPPI is that of a major biotech player with innovative drugs against severe diseases.

Yumame Foods provides healthy, sustainable and delicious food products based on fungi and fermentation.
Its branded food product is a tasty “Center of the Plate” that broadens the variety of today's animal alternative products. In a growing market with many new product launches, Yumame products are unique because they are minimally processed and locally produced, making them truly sustainable. Yumame Foods caters to a 400+M CHF market opportunity and aims to achieve 86M CHF in TO with 24% EBITDA margin in 2028.